Option Care Health (NASDAQ:OPCH) Earns “Outperform” Rating from Barrington Research

Barrington Research restated their outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a report released on Wednesday, Benzinga reports. Barrington Research currently has a $38.00 price target on the stock. Barrington Research also issued estimates for Option Care Health’s Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group raised their target price on Option Care Health from $36.00 to $38.00 and gave the stock a buy rating in a research note on Monday, March 4th.

Option Care Health Price Performance

Option Care Health stock opened at $29.93 on Wednesday. The firm has a market capitalization of $5.20 billion, a P/E ratio of 19.69, a PEG ratio of 1.74 and a beta of 1.22. Option Care Health has a one year low of $24.23 and a one year high of $35.74. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.77 and a quick ratio of 1.33. The business has a fifty day moving average price of $32.13 and a 200-day moving average price of $31.52.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings results on Tuesday, April 23rd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the business earned $0.21 EPS. The business’s revenue for the quarter was up 12.8% on a year-over-year basis. As a group, equities research analysts forecast that Option Care Health will post 1.13 EPS for the current year.

Insiders Place Their Bets

In other news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was purchased at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the transaction, the director now owns 269,528 shares of the company’s stock, valued at $8,503,608.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.64% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Option Care Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. Principal Securities Inc. purchased a new position in Option Care Health in the 4th quarter worth approximately $27,000. Parallel Advisors LLC lifted its holdings in Option Care Health by 130.2% during the 4th quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock valued at $28,000 after buying an additional 478 shares in the last quarter. TFO Wealth Partners LLC boosted its holdings in shares of Option Care Health by 24,625.0% in the fourth quarter. TFO Wealth Partners LLC now owns 989 shares of the company’s stock valued at $33,000 after purchasing an additional 985 shares during the period. First Horizon Advisors Inc. bought a new position in Option Care Health during the 3rd quarter worth about $37,000. Finally, Park Place Capital Corp increased its position in Option Care Health by 48.4% during the 1st quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock valued at $38,000 after purchasing an additional 372 shares during the period. 98.05% of the stock is currently owned by institutional investors.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.